Search 

iliod is a pharmaceutical development company aiming at developing a novel infective agent until phase II clinical trials. iliod is founded on the core assets of three patent applications, know-how and experience of the active protein, a network both within academia and industry and a dedicated team with a drive to make a difference for the future of healthcare.

Imaging Resource AB provides advanced microanalysis services of everything from pharmaceutical substances, packaging material, nanostructured surfaces to process equipment and mechanical components.
Scanning Electron Microscopy, as well as other specialized microscopy techniques, is used to increase the knowledge about the properties of your material. We handle projects in many industrial and R&D areas: Life Science, engineering, packaging, material science and product development.

We also create striking scientific illustrations based on Scanning Electron Micrographs. The outcome of your investment in an microscopy analysis can be doubled by refining the result to become fascinating images that can be used in the whole chain from development to marketing.

Immunicum AB (publ) develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX®, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Since the raw material consists of white blood cells (DCs) from healthy donors, Immunicum’s products can be mass-produced.

The therapeutic cancer vaccine INTUVAX® is injected intratumorally and is currently being evaluated in a clinical Phase I/II-study in metastatic renal cell carcinoma. It utilizes each patient’s own unique tumor tissue as antigen source and is thus a completely personalized therapeutic cancer vaccine that is still able to mass-produce and store in frozen condition for long periods of time.

Forskarpatent specialises in the commercialisation, through licensing or new venture spinouts, of patentable inventions emanating mainly from Swedish universities. At present Forskarpatent holds a portfolio of 15 different projects in the format of shares in spinouts, partnered (licensed) and still unpartnered assets.